morning. Good Lisa. And thank today. you you, joining Thank for all us
XXXX the it for will that challenging of Amarin, that filled year was a gives believe significant While the evolution for and for year a us our we foundation a was created company. tremendous also accomplishments XXXX be with future have confidence year
we in and that actions this be of able International. place, see turnaround the been see falls we clearly and in to each more the to remainder of year, beginning only growing the Throughout successful have XXXX, results into we building piece a the will XXXX. took as are We already business
U.S. are we product unique U.S. position increasing of in the facing is building as while outside the a value Amarin a market. in for competition genetic
is day because they being people vision disease made come cause stop Our bold to us. cardiovascular up who from what company is of This death. drives believe of our to vision a in work leading every
took of able I'm accomplish we as to for together, this and accomplishing on have I future what we the proud execute team what I'm to excited able Today, are our been to and we bring will to strategy. possible in over in briefly operational of continue we as the VAZKEPA excellence globe. value XXXX spirit summarize eligible the create VASCEPA, patients many the and term long actions of the as that in the across
with a our and the will in efforts. I the at our for the the I for also support XXXX. plans for in results will an where an global discuss we the upcoming of look update the U.S. our this with is meeting. team's efforts provide Amarin's commercialization remainder on provide for ahead where launch will guidance XXXX, on to presence stabilize conclude global Tom, our discuss fourth stand results briefly then expansion. update ACC our will our financial quarter will and then and the I business UK I providing at
global global added XXXX, we our in the have In beginning the market pricing XXXX to talent a commercialization, with markets. we Europe in with February. that year cash ended available Switzerland year European where on the in country sixth individual of five reimbursement have negotiating right We XXXX, on main execute and one Since received product three focused areas, strategy. we ensuring the in we new have preserving and began our our
have of and pricing an stages reimbursement five negotiations. advanced in also additional We markets European
building the sustainable a end to Our the revenue is in focus stream majority by on diverse conclude XXXX and we vast objective of Europe. as
we market, anticipate in confident progress. through in imminently. have our Spain, to ability round third two in gone the secure a this remain potential review pricing solid are and In we We made of and process rounds reimbursement active of review
on Netherlands changes of a are typically come markets. we advanced our these We the France, preserving also mid-year longer other in cash. than We're slightly making markets progressing our others expected Israel, are optimistic with are the such year. as Italy, price and Other in potential and also take progress In based and good for around focused could markets on historical Portugal, negotiations Norway, decisions can benchmarks. decision which this
$XXX Swift in action XXXX, we members team. almost supply to new with on of burn saw our million management purchase renegotiate quarter first cash the took a In We arrangements.
and a We are today, June, that target. exceed are saving we our we million cost cost implemented announce to comprehensive track saving in on $XXX plan to excited also
positive cash and in Thanks discuss details call. a flow will to fiscal our cutting million. more continued fourth These a end in discipline in more than balance quarter in which $XXX Tom year cash cost efforts, resulted actions later of the
respective lastly, And European product companies contacts, a organization product and from where successfully commercialized have they and extensive medical of expertise drugs in with members launches, built expertise, knowledge. affairs, and commercial blockbuster come also cardiovascular of Many markets. significant we strong knowledge with our their team
the had and to data, and our to successfully professionals leveraging brand that leading US unmatched they benefited background our valuable These This from colleagues years Europe. business experience brand are market. product, came the culture, utilizing their in and European our our US build several in Amarin also their the team over building and experience of entrepreneurial Amarin the because
the providing an now like UK. I'd on update on focus to
available I the patients. and highlights. of approval, in XXXX. the VASCEPA October of year guidelines securing on to in application XXXX, place national funding made VASCEPA of key focusing We provide July formularies, in First, which the begin for UK therapy final reminder spend of they later, days November in were NICE to our adding July to was XXXX, in and NHS XXXX, NICE published included the a of it's completed came think useful XX
steps the compared VASCEPA us these for we critical the positioned. we to in to extremely analogs help other art strong position and oral achievements launch UK, of and look of team. to this of effort pricing are a were in well Thanks, our When the market. establish local All large at
in VASCEPA treatment across efforts brings available volume Given local the are of UK. data the spectrum far pricing product perspective, and team the patients our of for this daily to the of oral in exceeds from conveying a value Cardiometabolic products the analogs price
the comparable the launches other of market. initial UK, in market When trending access is we look at of recent in VASCEPA market picture ahead the access
which the eligible patient XX% first UK. the VAZKEPA unlocked of accounts, population collectively represents XX has for team Our XX of out the priority in
the these growing the As a achieved, as UK and of reminder, terms VAZKEPA Based there that opportunity on a is believe we for historically is in price business viable in the revenue. trends a strong UK. a long-term slower market and initially
on to Europe. now global outside our expansion progress Moving of
set in distribution we exclusive in Zealand. we XXXX this a reminder, and six in in of XXXX, and to XXXX Seqirus As New objective achieved getting international an with approval between and We agreement received more important additional approval, Zealand. New Australia approvals And achieve than CSL license announced an we in following yesterday, regulatory out our XX markets. approvals regulatory XXXX, markets, already
patients New with are CSL commercialization market Seqirus efforts support teams to us positioned excited benefits that and record this access are and to medicine particularly world in brings this partner. with in CSL pharmaceutical and agreement distribution announce Seqirus, highly important Australia deliver pricing in Zealand a and promotion marketing to successfully help their pharmaceutical and VAZKEPA, and countries. experienced We for to well reimbursement supporting eventual class strong listings, to licensing these
both moving of it, it access patients and there. in of the direction that contributed Importantly, giving and to is physicians patients are Zealand so to the significant gratifying know we Australia to New product number reduce
We of to partner include Eddingpharm. expect the next wave China our through approvals
In in charge Edding our time latest of process the period regulatory mid-year the update, Regarding an of delays expect due in their a of process. to China China, shutdown result is the to of partner as restrictions. by COVID-XX regulatory they approval a for indicated related review Eddingpharm
to with our have ensure the very update closely working latest are We we partner. Edding from
today, for or regulatory open received of not any there the questions are product. regarding filing that have As any we our indication concerns
has Therapeutics in to a and continues phase of in the in payers, majority eligible Canada. sector access stronger the are public patients provinces, secured. private all public major gaining reimbursement HLS access HLS they public the and pain Canada, In product seeing from launch with to was a be in growth where
Central the extract hands markets. would and We value are of important product we potential regions, which to ensure from and get into clinicians enable the agreements Eastern Pacific and in negotiating patients, European can important also this Asia these actively us
future plans. creating for for We Europe is objective, as expansion in multi-billion-dollar and made have and our with for market we focused pleased I'm growth progress the on internationally, value in core advancing We confident VASCEPA/VAZKEPA expansion remain the to key the international. remain our global Europe community is expansion international VASCEPA/VAZKEPA and in believe shareholders. we which
fourth competition. of Moving revenue continued in U.S. of XXXX. with to stabilization four from we generic recorded in in net consecutive in Inline This despite the including of quarter quarter revenue U.S. and the plans last the in ECC million fourth quarter our for million XXXX, business the total pressure XXXX, is U.S. product $XX.X quarters our $XX sales.
care and experienced on efforts the and was This highly only the relentless unique managed team field the organizations. achievement dedication with possible through of U.S. our
to We are the market. share maintain our continuing IPE in
January in trends of support the stabilization business. and Our February continued
products quarter, In with patients quarter, healthcare U.S. calendar trends and from expect pharma in to resetting co-pays experiencing year. fourth branded we're deductibles like for seasonal quarter and typical that first the can a driven new by the first VASCEPA their plans
more this sales, will we billion generated continue some XXXX. compelling generic details what more to in expect than shortly. competition. our also see talk team in has we One $X We expect fact in erosion U.S. to is as experience launched that, generic year, about can price Tom since continued
multiple we maintain can our we to consider to levers And have continue profitability.
savings generic time. generic cost I as needed the and earlier, ability ahead our we or the brand authorized a an As either have right launch of plan are to at mentioned and
clear carefully in scenarios, nimble is it for strong we with near provides infrastructure we the While right are the to us term. in to business planning the retained potential and support U.S. that, stabilization continue today the team all
at the from to in week were have New continue data will that American with Cardiology, place College be meeting and generated benefit presented we four this strong later reduce of abstracts Orleans. Lastly, taking accepted we the
consistently reducer that of VASCEPA add are the of from to share excited findings risk populations We has trial treating high disease. wealth data cardiovascular new patients’ the that of at validated utility the to and
patients and comparing role the globally. of to help and should This important at-risk oil, reduce information with EPA the events coupled EPA, of of community's advance value the antioxidant DHA, and understanding medical effects in oil corn analyses mineral cardiovascular the an VASCEPA
to committed in remain our for a support the of focus VAZKEPA VASCEPA, global presence data and education We with world. to launches investing medical around our efforts medical the the
over With about quarter. that, this to and I'll progress more results talk our strong it to turn Tom? Tom
